EC approves Daklinza for the treatment of chronic hepatitis C patients
Bristol-Myers Squibb Company announced that the European Commission has approved Daklinza for the treatment of chronic hepatitis C (HCV) in three new patient populations
Source: Pharmacy Europe - Category: Drugs & Pharmacology Authors: Annabel De Coster Tags: *** Editor's Pick Clinical trials Practical therapeutics Patient care ALLY-1 ALLY-2 cirrhosis CYP3A daklinza hcv hiv-1 Latest News P-glycoprotein transporter post-liver transplant Sofosbuvir Source Type: news
More News: Cirrhosis | Clinical Trials | Drugs & Pharmacology | Hepatitis | Hepatitis C | Liver | Liver Transplant | Transplant Surgery | Transplants | Urology & Nephrology